Indoles

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (Ia)

• wherein
• X is C═O and Y is NR7, or
• X is CH2 and Y is O, or
• X is CH2 and Y is CH2,
• R1 is hydrogen,
• C1-6-alkyl, optionally substituted by CN or OH, or
• —(C1-6-alkylene)-C(O)—NRaRb;
• R2 is hydrogen,
• C1-6-alkyl,
• C1-6-alkoxy,
• —(C1-6-alkylene)-NRcRd,
• —(C1-6-alkylene)-C(O)Rf,
• benzyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano, or
• phenyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano;
• R3 is hydrogen,
• halo, or
• C1-6-alkyl;
• R4 is hydrogen,
• halo,
• C1-6-alkyl,
• halo-C1-6-alkyl,
• C1-6-alkoxy,
• halo-C1-6-alkoxy, or
• —O—C2-10-alkenyl;
• R5 is hydrogen,
• halo,
• C1-6-alkyl, or
• C1-6-alkoxy;
• R6 is hydrogen,
• C1-6-alkyl, optionally substituted by CN or OH,
• —(C1-6-alkylene)-NRgRh
• —(C1-6-alkylene)-C(O)—NRiRj
• —O-benzyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano,
• nitro,
• halo,
• cyano,
• C1-6-alkoxy,
• halo-C1-6-alkoxy,
• —(C1-6-alkylene)-C(O)Rf,
• phenyl, or 5 to 6-membered heteroaryl, optionally substituted by halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano,
• —(C1-3-alkylene)-Rm, wherein Rm is phenyl, a 5- to 6-membered heteroaryl, 4- to 6-membered heterocycloalkyl or 3 to 6-membered cycloalkyl,
• each optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano;
• R7 is hydrogen or C1-6-alkyl;
• R9, R10, and R11 are each independently hydrogen, halo, C1-6-alkyl, C1-6-alkoxy or halo-C1-6-alkoxy;
• Ra, Rb, Ri and Rj are each independently
• hydrogen,
• C1-6-alkyl,
• —(C1-6-alkylene)-NRkRl,
• wherein Rk and Rl are each independently hydrogen or C1-6-alkyl,
• or
• Ra and Rb, or Ri and Rj together with the nitrogen to which they are bound form a five or six membered heterocycle comprising one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
• Rc, Rd, Rg and Rh are each independently
• hydrogen,
• C1-6-alkyl,
• —C(O)Re, or —S(O)2Re,
• wherein Re is selected from
• hydrogen,
• C1-6-alkyl, or
• phenyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano, or
• Rc and Rd, or Rg and Rh together with the nitrogen to which they are bound form a five or six membered heterocycle comprising one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, or
• Rc and Rd, or Rg and Rh together with the nitrogen to which they are bound form isoindole-1,3-dione;
• Rf is selected from the group consisting of
• hydrogen,
• C1-6-alkyl,
• C1-6-alkoxy, or
• phenyl, optionally substituted by one or more halo, halo-C1-6-alkyl, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, nitro, or cyano;
• Rn, Ro and Rp are each independently selected from the group consisting of selected from the group consisting of hydrogen and C1-6-alkyl,
• or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.